Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

4-1BB-Costimulated CAR-Mediated Non-Canonical NF-Kb Signaling Enhances CAR T Cell Survival and Suppresses Bim Expression

Michael C. Milone, MD PhD, Roddy OConnor, PhD, Michael May, PhD, Steven Albelda, MD, Benjamin Philipson, BA

Blood (2018) 132 (Supplement 1): 3713.

https://doi.org/10.1182/blood-2018-99-119522

Published: 2018

Journal Articles

Optimized FVIII-Domain-Based Chimeric Antigen Receptors to Specifically Target FVIII Inhibitor-Producing B Cells in Hemophilia a

Vijay Bhoj, MD PhD, Lucy Li, Benjamin J. Samelson-Jones, MD PhD, Bhavya S Doshi, MD, Christoph Ellebrecht, MD, Aimee Payne, MD PhD, Valder R Arruda, MD PhD, Michael C. Milone, MD PhD

Blood (2018) 132 (Supplement 1): 2196.

https://doi.org/10.1182/blood-2018-99-120031

Published: 2018

Journal Articles

PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells

Luca Bernabei, Alfred L. Garfall, MD, J. Joseph Melenhorst, PhD, Simon F Lacey, PhD BS, Edward A. Stadtmauer, MD FACP, Dan T. Vogl, MD, Vanessa Gonzalez, Gabriela Plesa, MD, Regina M Young, PhD, Adam Waxman, MD, Bruce L Levine, PhD, Carl H June, MD, Michael C. Milone, MD PhD, Adam D. Cohen, MD

Blood (2018) 132 (Supplement 1): 1973.

https://doi.org/10.1182/blood-2018-99-119514

Published: 2018

Journal Articles

Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Adam D. Cohen, MD, J. Joseph Melenhorst, PhD, Alfred L. Garfall, MD, Simon F Lacey, PhD BS, Megan Davis, PhD, Dan T. Vogl, MD, Lifeng Tian, PhD, Vanessa Gonzalez, Iulian Pruteanu, PhD, Anne Marie Nelson, Gabriela Plesa, MD, Adam Waxman, MD, Regina M Young, PhD, Bruce L Levine, PhD, Carl H June, MD, Edward A. Stadtmauer, MD FACP, Michael C. Milone, MD PhD

Blood (2018) 132 (Supplement 1): 1974.

https://doi.org/10.1182/blood-2018-99-119665

Published: 2018

Journal Articles

Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma

Ehren Dancy, MD, Alfred L. Garfall, MD, Adam D. Cohen, MD, Joseph A Fraietta, PhD, Megan Davis, PhD, Bruce L Levine, PhD, Don L. Siegel, MD PhD, Edward A. Stadtmauer, MD FACP, Dan T. Vogl, MD, Adam Waxman, MD, Aaron P. Rapoport, MD, Michael C. Milone, MD PhD, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2018) 132 (Supplement 1): 1886.

https://doi.org/10.1182/blood-2018-99-115319

Published: 2018

Journal Articles

Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM)

Blood (2017) 130 (Supplement 1): 505.

https://doi.org/10.1182/blood.V130.Suppl_1.505.505

Published: 2017

Journal Articles

Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control

Saba Ghassemi, PhD, Patel Prachi, John Scholler, Selene Nunez-Cruz, PhD, David M. Barrett, MD PhD, Felipe Bedoya, PhD, Joseph A. Fraietta, PhD, Simon Francis Lacey, PhD BS, Bruce L Levine, PhD, Stephen A. Grupp, MD PhD, Carl H June, MD, Michael C. Milone, MD PhD, J. Joseph Melenhorst, PhD

Blood (2016) 128 (22): 4549.

https://doi.org/10.1182/blood.V128.22.4549.4549

Published: 2016

Journal Articles

B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study

Blood (2016) 128 (22): 1147.

https://doi.org/10.1182/blood.V128.22.1147.1147

Published: 2016

Journal Articles

Loss of Programmed Death Ligand-1 Expression on Donor T Cells Lessens Acute Graft-Versus-Host Disease Lethality

Blood (2015) 126 (23): 147.

https://doi.org/10.1182/blood.V126.23.147.147

Published: 2015

Journal Articles

Role of PD-1/PD-L1 in Acute and Chronic Graft Versus Host Disease

Bruce R. Blazar, MD, Roddy S. O'Connor, PhD, Michael C. Milone, MD PhD, Michael L. Dustin, PhD, James L. Riley, PhD, Benjamin G. Vincent, MD, Jonathan S. Serody, MD, Ryan P Flynn, PhD, Katelyn Paz, Jing Du, Angela Panoskaltsis-Mortari, PhD, Miller Jeffrey, MD, Rafi Ahmed, PhD, Laurence A. A. Turka, MD, Gordon J. Freeman, PhD, Arlene H. Sharpe, MDPhD, Asim Saha, PhD

Blood (2015) 126 (23): SCI-8.

https://doi.org/10.1182/blood.V126.23.SCI-8.SCI-8

Published: 2015

Journal Articles

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma

Marco Ruella, MD, Saad S Kenderian, MD, Olga Shestova, PhD, Joseph A. Fraietta, PhD, Sohail Qayyum, MD, Qian Zhang, MD PhD, Marcela V. Maus, MDPhD, Xiaobin Liu, PhD, Selene Nunez-Cruz, PhD, Michael Klichinsky, PharmD, Omkar Uday Kawalekar, MS, BS, Michael C. Milone, MD PhD, Simon F. Lacey, PhD BSc, Anthony Mato, MD, Stephen J. Schuster, MD, Michael Kalos, PhD, Carl H. June, MD, Saar I Gill, MBBS, PhD, Mariusz A. Wasik, MD

Blood (2015) 126 (23): 704.

https://doi.org/10.1182/blood.V126.23.704.704

Published: 2015

Journal Articles

Signaling Domain of Chimeric Antigen Receptors Can Reprogram T Cells

Omkar Uday Kawalekar, MS, BS, Roddy O'Connor, PhD, Sonia Guedan, PhD, Joseph Fraietta, PhD, Avery D. Posey, PhD, John Scholler, Michael C Milone, MD PhD, Carl H. June, MD

Blood (2014) 124 (21): 551.

https://doi.org/10.1182/blood.V124.21.551.551

Published: 2014

Journal Articles

Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy

Vijay Bhoj, MD PhD, Michael C Milone, MD PhD, Carl H. June, MD, David Porter, MD, Stephan A. Grupp, MD PhD, Jan J Melenhorst, PhD, Simon F. Lacey, PhD BSc, Colleen Callahan, MSN, CRNP, James Capobianchi, Gerald Wertheim, MDPhD, Yolanda Mahnke, PhD

Blood (2014) 124 (21): 1110.

https://doi.org/10.1182/blood.V124.21.1110.1110

Published: 2014

Journal Articles

Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL

David L Porter, MD, Stephan A. Grupp, MD, PhD, Michael Kalos, PhD, Alison W. Loren, MD, Lester Lledo, CRNP, Joan Gilmore, Michael C Milone, MD, PhD, Anne Chew, PhD, Bruce L. Levine, PhD, Carl H. June, MD

Blood (2012) 120 (21): 717.

https://doi.org/10.1182/blood.V120.21.717.717

Published: 2012

Journal Articles

Chimeric Immunoreceptor (T-Body) Targeting of Acute B-Cell Lymphoblastic Leukemia (B-ALL) through Lentivirus Engineering of Primary Human T Cells.

Michael C. Milone, MD, PhD, Jonathan Fish, MD, Carmine Carpenito, PhD, Mehdi Lakal, BS, Ella Ofori, BS, Gwenn Danet-Desnoyers, PhD, James L. Riley, PhD, Stephan A. Grupp, MD, PhD, Carl H. June, MD

Blood (2006) 108 (11): 3267.

https://doi.org/10.1182/blood.V108.11.3267.3267

Published: 2006

Journal Articles

Sleeping Beauty (SB) Transposon Mediated Umbilical Cord Blood (UCB) T Cell Therapy for Refractory Acute Lymphoblastic Leukemia (ALL).

Xianzheng Zhou, MD, PhD, Xin Huang, MD, Johnthomas Kang, PhD, Hongfeng Guo, MD, PhD, Suet Choi, Preetinder Bassi, Tom C. Zhou, Michael C. Milone, MD, PhD, Bruce L. Levine, PhD, Carl H. June, MD, R. Scott McIvor, PhD, John E. Wagner, MD, Bruce R. Blazar, MD

Blood (2006) 108 (11): 722.

https://doi.org/10.1182/blood.V108.11.722.722

Published: 2006

NARROW

4-1BB-Costimulated CAR-Mediated Non-Canonical NF-Kb Signaling Enhances CAR T Cell Survival and Suppresses Bim Expression

Optimized FVIII-Domain-Based Chimeric Antigen Receptors to Specifically Target FVIII Inhibitor-Producing B Cells in Hemophilia a

PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells

Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma

Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM)

Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control

B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study

Loss of Programmed Death Ligand-1 Expression on Donor T Cells Lessens Acute Graft-Versus-Host Disease Lethality

Role of PD-1/PD-L1 in Acute and Chronic Graft Versus Host Disease

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma

Signaling Domain of Chimeric Antigen Receptors Can Reprogram T Cells

Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy

Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL

Chimeric Immunoreceptor (T-Body) Targeting of Acute B-Cell Lymphoblastic Leukemia (B-ALL) through Lentivirus Engineering of Primary Human T Cells.

Sleeping Beauty (SB) Transposon Mediated Umbilical Cord Blood (UCB) T Cell Therapy for Refractory Acute Lymphoblastic Leukemia (ALL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only